Medicaid expansion under the ACA improved long-term survival for younger adults with operable lung cancer, despite no earlier ...
About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...
Zipalertinib showed a 35% overall response rate in EGFR exon 20 mutated NSCLC, with notable CNS activity and a favorable safety profile. NeoADAURA trial highlighted the feasibility of neoadjuvant EGFR ...
Patterns of confirmatory germline testing in patients with somatic BRCA1/2 pathogenic variants across solid tumor types in a community oncology setting. Risk of hypertension in patients newly ...
Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved ...
Please provide your email address to receive an email when new articles are posted on . “We believe that these results are quite powerful and informative,” Christopher Seder, MD, thoracic surgeon at ...
The Phase 1b/2 SCLC trial and Phase 2 VIRO-25 trial are actively enrolling in dose escalation cohorts with an aim to optimize efficacy, safety, and tolerability of Olvi-Vec. The trials are being ...
From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...
Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...
Trethera Corp. received a $2.7M NIH grant to study combining TRE-515 with KRAS inhibitors for lung cancer. Learn how this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback